<DOC>
	<DOCNO>NCT02716012</DOCNO>
	<brief_summary>This First Human study new single agent ( MTL-CEBPA ) patient advanced cancer liver . The study two part . The first part dose escalation patient advance hepatocellular carcinoma patient present secondary liver tumour . The second part dose expansion study patient hepatocellular carcinoma . All participant refractory ineligible loco-regional therapy include surgery , radiofrequency tumour ablation transarterial chemoembolisation sorafenib . MTL-CEBPA consist double strand RNA formulate SMARTICLES® liposomal nanoparticle design activate CEBPA gene .</brief_summary>
	<brief_title>First-in-Human Safety Tolerability Study MTL-CEBPA Patients With Advanced Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Histologically confirm advanced advanced cancer characterise hepatocellular carcinoma ( HCC ) advance stage cancer present secondary liver tumour derive extra hepatic primary cancer type . At least one measurable lesion target lesion size ≥ 1.0 cm measure MRI CT Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ChildPugh A B7 disease ( HCC ) Willing provide archive tumor tissue ( available ) willing undergo pre ontreatment tumor biopsy ( consider safe medically feasible treat investigator ) Central nervous system metastases Signs symptom heart failure characterise great New York Heart Association ( NYHA ) Class I Patient present prolonged correct QT ( QTc ) interval define ≥ 450ms ( male ) ≥ 460ms ( female ) use Fridericia 's correction formula ; clinically significant cardiac abnormality . Platelets &lt; 75 x 10^9/L Absolute neutrophil count &lt; 1.5 x 10^9/L Serum albumin ≤ 28 g/L ( patient cirrhosis ) Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5 x Upper Limit Normal ( ULN ) Bilirubin &gt; 50 μmol /L Haemoglobin ≥ 9.0 g/dL Prothrombin time ( PT ) ≥ 20 second Serum creatinine &gt; 1.5 x ULN Estimated creatinine clearance &lt; 60 mL/min/1.73 m2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oligonucleotide</keyword>
	<keyword>RNA</keyword>
	<keyword>saRNA</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>